Cancer Drug Shows Potent Activity in the Lab Against SARS-CoV-2, Including New Variants

In two preclinical models of COVID-19, plitidepsin showed a 100-fold reduction in viral replication in the lungs and demonstrated an ability to reduce lung inflammation.